Heron Therapeutics, Inc. (FRA:AXD2)
Germany · Delayed Price · Currency is EUR 0.9455
+0.0020 (0.21%)
At close: Nov 28, 2025
Heron Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 155.1 | 144.29 | 127.04 | 107.67 | 86.35 | 88.64 | Upgrade | |
Revenue Growth (YoY) | 12.60% | 13.57% | 17.99% | 24.70% | -2.59% | -39.28% | Upgrade |
Cost of Revenue | 52.32 | 55.33 | 100.24 | 133.38 | 175.64 | 209.52 | Upgrade |
Gross Profit | 102.78 | 88.95 | 26.81 | -25.71 | -89.3 | -120.88 | Upgrade |
Selling, General & Admin | 101.18 | 100.48 | 119.82 | 143.55 | 127.13 | 101.68 | Upgrade |
Operating Expenses | 101.18 | 100.48 | 119.82 | 143.55 | 127.13 | 101.68 | Upgrade |
Operating Income | 1.6 | -11.53 | -93.02 | -169.26 | -216.43 | -222.56 | Upgrade |
Interest Expense | -7.43 | -6.03 | -3.87 | -2.47 | -2.41 | -1.9 | Upgrade |
Interest & Investment Income | 3.55 | 3.55 | 3.36 | 1.64 | 0.43 | 3.63 | Upgrade |
Other Non Operating Income (Expenses) | 1.95 | 4.83 | 1.18 | -6.32 | -0.4 | - | Upgrade |
EBT Excluding Unusual Items | -0.34 | -9.18 | -92.34 | -176.42 | -218.81 | -220.83 | Upgrade |
Merger & Restructuring Charges | - | - | -4.2 | -5.4 | -1.4 | -5.6 | Upgrade |
Gain (Loss) on Sale of Investments | 0.01 | 0.01 | -0 | - | - | - | Upgrade |
Asset Writedown | -1.91 | -4.41 | -0.62 | -0.21 | -0.48 | -0.85 | Upgrade |
Other Unusual Items | -11.34 | - | -13.4 | - | - | - | Upgrade |
Pretax Income | -13.58 | -13.58 | -110.56 | -182.02 | -220.68 | -227.28 | Upgrade |
Net Income | -13.58 | -13.58 | -110.56 | -182.02 | -220.68 | -227.28 | Upgrade |
Net Income to Common | -13.58 | -13.58 | -110.56 | -182.02 | -220.68 | -227.28 | Upgrade |
Shares Outstanding (Basic) | 158 | 152 | 138 | 109 | 98 | 91 | Upgrade |
Shares Outstanding (Diluted) | 158 | 152 | 138 | 109 | 98 | 91 | Upgrade |
Shares Change (YoY) | 3.91% | 10.36% | 26.87% | 10.57% | 8.48% | 11.00% | Upgrade |
EPS (Basic) | -0.09 | -0.09 | -0.80 | -1.67 | -2.24 | -2.50 | Upgrade |
EPS (Diluted) | -0.09 | -0.09 | -0.80 | -1.67 | -2.24 | -2.50 | Upgrade |
Free Cash Flow | -31.14 | -24.24 | -60.33 | -148.74 | -206.38 | -191.63 | Upgrade |
Free Cash Flow Per Share | -0.20 | -0.16 | -0.44 | -1.37 | -2.10 | -2.11 | Upgrade |
Gross Margin | 66.27% | 61.65% | 21.10% | -23.87% | -103.42% | -136.38% | Upgrade |
Operating Margin | 1.03% | -7.99% | -73.22% | -157.20% | -250.65% | -251.09% | Upgrade |
Profit Margin | -8.76% | -9.41% | -87.02% | -169.05% | -255.58% | -256.41% | Upgrade |
Free Cash Flow Margin | -20.08% | -16.80% | -47.49% | -138.14% | -239.01% | -216.20% | Upgrade |
EBITDA | 3.96 | -9.04 | -90.12 | -166.37 | -213.41 | -219.72 | Upgrade |
EBITDA Margin | 2.55% | -6.26% | -70.93% | -154.52% | -247.15% | -247.88% | Upgrade |
D&A For EBITDA | 2.36 | 2.49 | 2.9 | 2.89 | 3.02 | 2.85 | Upgrade |
EBIT | 1.6 | -11.53 | -93.02 | -169.26 | -216.43 | -222.56 | Upgrade |
EBIT Margin | 1.03% | -7.99% | -73.22% | -157.20% | -250.65% | -251.09% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.